-
The authors compared potential risk factors, clini-cal symptoms, diagnostic delay, and 3-month outcome between spontaneous internal carotid artery dissection (sICAD) and spontaneous vertebral artery dissection (sVAD).
-
In patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity.
-
The impression is acute infero-posterior infarction, with possible lateral and right ventricular involvement. In most patients, the right coronary artery (RCA) supplies the right ventricle and posterior and inferior walls of the left ventricle.
-
The fda has approved a higher dose of the rivastigmine transdermal system (13.3 mg/24 hours) for the treatment of Alzheimer's disease (AD). Lower-dose patches were previously approved for mild-to-moderate disease. Rivastigamine is a reversible acetylcholinesterase inhibitor. The transdermal system is marketed by Novartis as Exelon.
-
The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial randomized 1376 patients with AF and CHF to rhythm- or rate-control treatment strategies.
-
This study examines the influence of renal dysfunction on stroke risks in two atrial fibrillation (AF) study groups. The ROCKET AF trial was a trial comparing fixed-dose rivaroxaban, a direct factor Xa inhibitor, with adjusted-dose warfarin for prevention of thromboembolic events.
-
Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
-
The accurate and timely recognition of acute coronary syndromes (ACS) may facilitate the deployment of evidence-based therapies that could impact outcomes.
-
Beta-blockers are widely considered first-line therapy for heart rate control in patients with permanent atrial fibrillation (AF), but few comparative effectiveness data with other drugs are available.
-
During coronary artery bypass graft (CABG) surgery, the aim is to achieve complete revascularization of all the coronary arteries.
